Publications of T. Prukop

Prukop, T.; Wernick, S.; Boussicault, L.; Ewers, D.; Jäger, K.; Adam, J.; Winter, L.; Quintes, S.; Linhoff, L.; Barrantes‐Freer, A. et al.; Bartl, M.; Czesnik, D.; Zschüntzsch, J.; Schmidt, J.; Primas, G.; Laffaire, J.; Rinaudo, P.; Brureau, A.; Nabirotchkin, S.; Schwab, M. H.; Nave, K.-A.; Hajj, R.; Cohen, D.; Sereda, M. W.: Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats. Journal of Neuroscience Research 98 (10), pp. 1933 - 1952 (2020)

Prukop, T.; Stenzel, J.; Wernick, S.; Kungl, T.; Mroczek, M.; Adam, J.; Ewers, D.; Nabirotchkin, S.; Nave, K.-A.; Hajj, R. et al.; Cohen, D.; Sereda, M. W.: Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PLoS One 14 (1), e0209752 (2019)

Fledrich, R.; Abdelaal, T. A. M.; Rasch, L.; Bansal, V.; Schütza, V.; Brügger, B.; Lüchtenborg, C.; Prukop, T.; Stenzel, J.; Rahman, R.U. et al.; Hermes, D.; Ewers, D.; Möbius, W.; Ruhwedel, T.; Katona, I.; Weis, J.; Klein, D.; Martini, R.; Brück, W.; Müller, W.C.; Bonn, S.; Bechmann, I.; Nave, K.-A.; Stassart, R. M.; Sereda, M. W.: Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nature Communications 9, 3025 (2018)

Fledrich, R.; Mannil, M.; Leha, A.; Ehbrecht, C.; Solari, A.; Pelayo-Negro, A. L.; Berciano, J.; Schlotter-Weigel, B.; Schnizer, T. J.; Prukop, T. et al.; Garcia-Angarita, N.; Czesnik, D.; Haberlová, J.; Mazanec, R.; Paulus, W.; Beissbarth, T.; Walter, M. C.; CMT-TRIAAL; Hogrel, J.-Y.; Dubourg, O.; Schenone, A.; Baets, J.; De Jonghe, P.; Shy, M. E.; Horvath, R.; Pareyson, D.; Seeman, P.; Young, P.; Sereda, M. W.: Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. Journal of Neurology, Neurosurgery & Psychiatry 88 (11), pp. 941 - 952 (2017)

Sociali, G.; Visigalli, D.; Prukop, T.; Cervellini, I.; Mannino, E.; Venturi, C.; Bruzzone, S.; Sereda, M. W.; Schenone, A.: Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. Neurobiology of Disease 95 (11), pp. 145 - 157 (2016)

Epplen, D. B.; Prukop, T.; Nientiedt, T.; Albrecht, P.; Arlt, F. A.; Stassart, R. M.; Kassmann, C. M.; Methner, A.; Nave, K.-A.; Werner, H. B. et al.; Sereda, M. W.: Curcumin therapy in a Plp1 transgenic mouse model of Pelizaeus-Merzbacher disease. Annals of Clinical and Translational Neurology 2 (8), pp. 787 - 796 (2015)

Fledrich, R.; Stassart, R. M.; Klink, A.; Rasch, L. M.; Prukop, T.; Haag, L.; Czesnik, D.; Kungl, T.; Abdelaal, T. A. M.; Keric, N. et al.; Stadelmann, C.; Brück, W.; Nave, K.-A.; Sereda, M. W.: Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. Nature Medicine 20 (9), pp. 1055 - 1061 (2014)

Prukop, T.; Epplen, D. B.; Nientiedt, T.; Wichert, S. P.; Fledrich, R.; Stassart, R. M.; Rossner, M. J.; Edgar, J. M.; Werner, H. B.; Nave, K.-A. et al.; Sereda, M. W.: Progesterone antagonist therapy in a Pelizaeus-Merzbacher mouse model. The American Journal of Human Genetics 94 (4), pp. 533 - 546 (2014)

Meyer zu Hörste, G.; Prukop, T.; Liebetanz, D.; Möbius, W.; Nave, K.-A.; Sereda, M. W.: Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Annals of Neurology 61 (1), pp. 61 - 72 (2007)

Meyer zu Hörste, G.; Prukop, T.; Nave, K.-A.; Sereda, M. W.: Myelin disorders: causes and perspectives of Charcot-Marie-Tooth neuropathy. Journal of Molecular Neuroscience 28 (1), pp. 77 - 88 (2006)